Evommune is a clinical-stage biotechnology company developing therapies that target key drivers of chronic immune-mediated inflammation. Early clinical programs address chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis with candidates such as EVO756 and EVO301. The focus is on improving day-to-day disease control and reducing long-term damage from uncontrolled inflammation where existing options fall short.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 0 | — | -22.2 | — |
| Q3 2025 | 10 | — | -12.5 | — |
| Q4 2025 | 0 | — | -28.3 | — |
| Q1 2026 | 0 | — | -21.7 | — |
| Q2 2026 | 0 | — | -32.3 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: Ginkgo Bioworks Holdings, Inc. (DNA), Invesco Senior Income Trust (VVR), Natural Gas Services Group, Inc. (NGS), AdvanSix Inc. (ASIX), Bally's Corporation (BALY), Farmland Partners Inc. (FPI)